Use of Immune Modulating Agents to Regulate Hyperinflammation in Severe COVID 19: Assessment of Tocilizumab Use in Combination with Steroids
In all evaluated parameters, a low-dose steroid followed by tocilizumab was superior to a high-dose steroid alone or combined with tocilizumab. Although this combination treatment has been assessed worldwide, few studies have focused on its application in Iranian patients with severe COVID-19.
Authors
- Mozhdeh Saghaei
- Fereshteh Tavakoli
- Zohre Naderi (ORCID: https://orcid.org/0000-0002-0554-6067)
- Mahsa Hajizadeh
- Somayeh Sadeghi (ORCID: https://orcid.org/0000-0003-4287-1720)
- Nima Arezoomandi
Institutions
- Isfahan University of Medical Sciences (IR)
- Johns Hopkins University (US)
Publication Details
- Journal
- Journal of Research in Pharmacy Practice
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/jrpp.jrpp_2_25
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39